Maligne Hyperthermie – Pathophysiologie, Diagnostik und Therapie

Zusammenfassung

Die maligne Hyperthermie ist ein heterogenes klinisches Syndrom, bei dem es nach Exposition mit volatilen Anästhetika und/oder dem depolarisierenden Muskelrelaxans Succinylcholin zu einer gesteigerten Stoffwechselaktivität der Skelettmuskulatur mit zum Teil lebensbedrohlichen systemischen Auswirkungen auf Herz-Kreislauf-Funktionen, Körpertemperatur und Säure-Basen-Haushalt kommt. Der Beitrag gibt einen aktuellen Überblick über dieses seltene Krankheitsbild.

Abstract

Malignant hyperthermia (MH) is a rare, heterogenic syndrome leading to potentially life-threatening skeletal muscle hypermetabolism following exposure to inhalational anesthetics and succinylcholine. In more than 50% of affected individuals a pathogenic variant in the RYR1 gene coding for the sarcoplasmic reticulum calcium channel is responsible for the underlying pathology of uncontrolled calcium liberation. While the genetic prevalence of MH is as high as 1 : 2750, the incidence of clinical MH reactions is considerably lower, suggesting a dominant pattern of inheritance with incomplete penetrance. During acute MH crisis presenting with characteristic symptoms like hypercarbia, tachycardia, acidosis, hyperthermia, generalized muscular rigidity and rhabdomyolysis, discontinuation of triggering agents and immediate treatment with dantrolene 2.5 mg/kg are vital therapeutic interventions to control the reaction. A predisposition to MH should be investigated in patients following a suspected MH crisis, in relatives from MH-families, after exertional or unexplained perioperative rhabdomyolysis and in patients with idiopathic hyper-CK-aemia. According to recent European guidelines, initial DNA screening is an alternative to muscle biopsy and in-vitro contracture testing, although in cases where no diagnostic variants are found, only contracture testing can safely exclude predisposition to MH.

Schlüsselwörter

maligne Hyperthermie - Ryanodinrezeptor 1 - Dantrolen - Skelettmuskel

Key words

malignant hyperthermia - ryanodine receptor 1 - dantrolene - skeletal muscle

• Literatur

• 1 Denborough MA, Lovell RR. Anaesthetic deaths in a family. Lancet 1960; 276: 45
• 2 Schuster F, Moegele S, Johannsen S. et al. Malignant hyperthermia in the intensive care setting. Crit Care 2014; 18: 411
• 3 Larach MG, Brandom BW, Allen GC. et al. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007–2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg 2014; 119: 1359-1366
• 4 Hopkins PM, Gupta PK, Bilmen JG. Malignant hyperthermia. Handb Clin Neurol 2018; 157: 645-661
• 5 Larach MG, Gronert GA, Allen GC. et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110: 498-507
• 6 OʼFlynn RP, Shutack JG, Rosenberg H. et al. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis. Anesthesiology 1994; 80: 1228-1233
• 7 Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth 2011; 107: 48-56
• 8 Riazi S, Larach MG, Hu C. et al. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg 2014; 118: 381-387
• 9 Rosenberg H, Pollock N, Schiemann A. et al. Malignant hyperthermia: a review. Orphanet J Rare Dis 2015; 10: 93
• 10 Larach MG, Localio AR, Allen GC. et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779
• 11 Glahn KP, Ellis FR, Halsall PJ. et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth 2010; 105: 417-420
• 12 Klingler W, Roewer N, Schuster F. et al. S1 Leitlinie: Therapie der malignen Hyperthermie. Anästh Intensivmed 2018; 59: 204-208
• 13 Bilmen JG, Hopkins PM. The use of charcoal filters in malignant hyperthermia: have they found their place?. Anaesthesia 2019; 74: 13-16
• 14 Schuster F, Johannsen S. Maligne Hyperthermie: Pharmakologische Therapie – Update 2019. Anasthesiol Intensivmed Notfallmed Schmerzther 2019; 54: 549-558
• 15 Wappler F. [S1 guidelines on malignant hyperthermia: Update 2018]. Anaesthesist 2018; 67: 529-532
• 16 Riazi S, Kraeva N, Hopkins PM. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept. Anesthesiology 2018; 128: 168-180
• 17 Riazi S, Kraeva N, Hopkins PM. Updated guide for the management of malignant hyperthermia. Can J Anaesth 2018; 65: 709-721
• 18 European Malignant Hyperthermia Group. Diagnostic MH Mutations in RYR1 and CACNA1S. Im Internet: http://www.emhg.org/diagnostic-mutations Stand: 27.01.2019
• 19 Dlamini N, Voermans NC, Lillis S. et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord 2013; 23: 540-548
• 20 Hopkins PM, Ruffert H, Snoeck MM. et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth 2015; 115: 531-539
• 21 Girard T, Bandschapp O. Maligne Hyperthermie – Diagnostik konkret. Anasthesiol Intensivmed Notfallmed Schmerzther 2019; 54: 538-548